Mitiglinide
Based on 2 publication(s) in Google Scholar
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 145375-43-5
- Formel: C19H25NO3
- Molecular Weight:315.41
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mitiglinide
More
Biologische Aktivität
KATP channel[1]
Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pregnant Wistar rats (12 weeks)[2]
-
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
-
Administration:Oral administration
-
Result:Dose-dependently suppressed AUCglucose levels.
Chemical Information
-
CAS. Nr. 145375-43-5
-
Molecular Weight 315.41
-
Formel C19H25NO3
-
SMILES
O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C(O)=O)CC3=CC=CC=C3
-
Synonyms
KAD-1229 free acid anhydrous; S21403 free acid anhydrous
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
High-throughput screening identifies FDA approved drug mitiglinide as a novel pyroptosis inhibitor and therapeutic agent for osteoarthritis. [Abstract]2025 Dec 11:S2090-1232(25)00994-4. PMID: 41386507 -
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543
Reinheit & Dokumentation
Verweise
[1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. [Content Brief]
[2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Powered by Bioz